Foghorn therapeutics provides an update on fhd-609

Cambridge, mass., april 24, 2023 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced an update on the fhd-609 program in synovial sarcoma and smarcb1-deleted tumors.

FHTX Ratings Summary

FHTX Quant Ranking